Why the study?
Does HE3286 improve histological and immunohistochemical signs of myocarditis in BALB/c mice infected with coxsackie B3 virus compared to dexamethasone or vehicle?
Population
BALB/c mice infected with coxsackie B3 virus (CB3V)
Comparison
HE3286 administered by oral gavage for 18 days vs Dexamethasone administered intraperitoneally or…
Design
Preclinical
Follow-up
18 days
Key result
Oral administration of HE3286 resulted in an almost complete resolution of CVB-induced myocarditis in mice, demonstrating better efficacy than dexamethasone in reducing the inflammatory response.
Authors
Loading...
Requires clinical validation before any therapeutic consideration; leaves open translation from this murine model.
Does HE3286 improve histological and immunohistochemical signs of myocarditis in BALB/c mice infected with coxsackie B3 virus compared to dexamethasone or vehicle?
HE3286 showed superior efficacy to dexamethasone in resolving inflammation and tissue remodeling in a murine model of viral myocarditis.
Castrogiovanni et al. (2016) studied CVB-induced myocarditis. HE3286 vs. Dexamethasone or vehicle (HERF405) was evaluated on Histological signs of CVB-induced myocarditis and immunohistochemical analysis. Oral administration of HE3286 resulted in an almost complete resolution of CVB-induced myocarditis in mice, demonstrating better efficacy than dexamethasone in reducing the inflammatory response.